Bridgewater Associates LP Purchases New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bridgewater Associates LP bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,002 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

Other hedge funds have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $26,000. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $45,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.0 %

Shares of ALNY opened at $253.01 on Tuesday. The business’s 50 day moving average is $271.07 and its 200 day moving average is $242.32. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a market capitalization of $32.63 billion, a PE ratio of -97.31 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The business’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ALNY. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Chardan Capital restated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, TD Cowen increased their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.